BioNTech is acquiring CureVac in a $1.25 billion all-stock deal, resolving ongoing mRNA patent litigation and gaining CureVac’s advanced manufacturing capabilities. This strategic purchase enhances BioNTech’s cancer immunotherapy ambitions amid continued innovation in mRNA technologies. Analysts view the acquisition as a move to sidestep costly legal risks and solidify BioNTech’s position in next-generation therapeutic development.